Adma Biologics, Inc. ADMA
We take great care to ensure that the data presented and summarized in this overview for ADMA BIOLOGICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ADMA
View all-
Black Rock Inc. New York, NY18.6MShares$367 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$359 Million0.01% of portfolio
-
State Street Corp Boston, MA14.9MShares$293 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA11.3MShares$223 Million0.04% of portfolio
-
Morgan Stanley New York, NY5.53MShares$109 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA5.43MShares$107 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX4.67MShares$92 Million0.02% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL4.55MShares$89.7 Million0.02% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M3.88MShares$76.4 Million0.03% of portfolio
-
American Century Companies Inc Kansas City, MO3.77MShares$74.3 Million0.04% of portfolio
Latest Institutional Activity in ADMA
Top Purchases
Top Sells
About ADMA
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Insider Transactions at ADMA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 19
2025
|
Adam S Grossman President and CEO |
SELL
Open market or private sale
|
Direct |
21,000
-0.51%
|
$378,000
$18.92 P/Share
|
|
Mar 19
2025
|
Adam S Grossman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+0.72%
|
$75,000
$5.4 P/Share
|
|
Mar 07
2025
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
SELL
Payment of exercise price or tax liability
|
Direct |
3,935
-0.77%
|
$66,895
$17.02 P/Share
|
|
Mar 07
2025
|
Adam S Grossman President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
29,513
-1.41%
|
$501,721
$17.02 P/Share
|
|
Mar 06
2025
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
SELL
Payment of exercise price or tax liability
|
Direct |
8,881
-1.7%
|
$142,096
$16.91 P/Share
|
|
Mar 06
2025
|
Adam S Grossman President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
56,438
-2.62%
|
$903,008
$16.91 P/Share
|
|
Feb 26
2025
|
Brad L. Tade CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,280
-2.02%
|
$79,200
$15.78 P/Share
|
|
Feb 26
2025
|
Adam S Grossman President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
54,867
-2.48%
|
$823,005
$15.78 P/Share
|
|
Feb 25
2025
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
SELL
Payment of exercise price or tax liability
|
Direct |
1,855
-0.35%
|
$27,825
$15.44 P/Share
|
|
Feb 25
2025
|
Adam S Grossman President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
18,018
-0.81%
|
$270,270
$15.44 P/Share
|
|
Feb 19
2025
|
Alison Cecily Finger |
BUY
Grant, award, or other acquisition
|
Direct |
10,889
+23.77%
|
-
|
|
Feb 19
2025
|
Jerrold B Grossman |
BUY
Grant, award, or other acquisition
|
Direct |
10,889
+2.23%
|
-
|
|
Feb 19
2025
|
Steve Elms |
BUY
Grant, award, or other acquisition
|
Direct |
10,889
+11.09%
|
-
|
|
Feb 19
2025
|
Lawrence P. Guiheen |
BUY
Grant, award, or other acquisition
|
Direct |
10,889
+6.2%
|
-
|
|
Feb 19
2025
|
Eduardo Rene Salas |
BUY
Grant, award, or other acquisition
|
Direct |
10,889
+50.0%
|
-
|
|
Feb 19
2025
|
Young Kwon |
SELL
Grant, award, or other acquisition
|
Direct |
10,889
-4.14%
|
-
|
|
Feb 19
2025
|
Adam S Grossman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
252,022
+10.17%
|
-
|
|
Feb 19
2025
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
BUY
Grant, award, or other acquisition
|
Direct |
77,784
+12.93%
|
-
|
|
Feb 19
2025
|
Brad L. Tade CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
62,227
+19.21%
|
-
|
|
Jan 30
2025
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
SELL
Payment of exercise price or tax liability
|
Direct |
3,355
-0.75%
|
$53,680
$16.1 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 711K shares |
|---|---|
| Exercise of conversion of derivative security | 825K shares |
| Open market or private sale | 1.04M shares |
|---|---|
| Payment of exercise price or tax liability | 273K shares |
| Bona fide gift | 10K shares |
| Other acquisition or disposition | 460K shares |
| Grant, award, or other acquisition | 10.9K shares |